Cefpirome
Alternative Names: Broact; Cefpirome sulfate; Cefrom; HR 810; KeitenLatest Information Update: 05 Nov 2023
At a glance
- Originator sanofi-aventis
- Developer Chugai Pharmaceutical; Sanofi; sanofi-aventis
- Class Antibacterials; Cephalosporins; Small molecules
- Mechanism of Action Cell wall inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Marketed Bacterial infections
Most Recent Events
- 15 Aug 2007 Discontinued - Phase-I for Bacterial infections in USA (IV)
- 15 Aug 2007 Discontinued - Phase-III for Bacterial infections in Canada (IV)
- 11 Apr 2005 Yamanouchi has merged with Fujisawa to form Astellas Pharma